$IONS
IONIS PHARMACEUTICALS INC Stock $ions

$ions Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000110465912074712 Filed on November 06, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$19.87M	$11.60M	$20.71M
YoY Change	-38.67%	-43.99%	-27.58%
Cost Of Revenue	$42.60M
YoY Change
Gross Profit	-$22.70M
YoY Change
Gross Profit Margin	-114.23%
Selling, General & Admin	$3.200M	$3.100M	$3.100M
YoY Change	-15.79%	0.0%	6.9%
% of Gross Profit
Research & Development		$35.60M	$39.92M
YoY Change		-10.83%	15.05%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$45.99M	$39.65M	$43.03M
YoY Change	-9.85%	-7.86%	14.44%
Operating Profit	-$26.12M	-$28.05M	-$22.32M
YoY Change	40.3%	25.68%
Interest Expense	$15.10M	$5.937M	$4.773M
YoY Change	-1178.57%	24.39%	-236.37%
% of Operating Profit
Other Income/Expense, Net	-$231.4M
YoY Change
Pretax Income	-$242.4M	-$38.35M	-$26.88M
YoY Change	1112.0%	42.64%	115.06%
Income Tax	-$8.400M	-$706.0K	$0.00
% Of Pretax Income
Net Earnings	-$234.0M	-$37.60M	-$26.90M
YoY Change	1070.0%	39.78%	115.2%
Net Earnings / Revenue	-1177.48%	-324.11%	-129.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.03	-$0.37	-$0.27
COMMON SHARES
Basic Shares Outstanding	101.2M shares	100.7M shares	99.69M shares
Diluted Shares Outstanding		100.7M shares	99.69M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$374.4M	$343.6M	$364.8M
YoY Change	8.96%	-5.82%	-26.73%
Cash & Equivalents	$124.5M	$84.56M	$55.26M
Short-Term Investments	$250.0M	$259.0M	$309.5M
Other Short-Term Assets	$8.727M	$7.800M	$7.600M
YoY Change	61.16%	2.63%	20.63%
Inventory	$6.100M	$6.700M	$2.900M
Prepaid Expenses
Receivables	$500.0K	$3.500M	$1.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$423.4M	$361.6M	$377.1M
YoY Change	17.58%	-4.11%	-25.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$91.08M	$92.60M	$98.00M
YoY Change	-5.72%	-5.51%	176.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		-$5.563M
YoY Change
Other Assets	$5.900M	$6.100M	$3.100M
YoY Change	110.71%	96.77%	-16.22%
Total Long-Term Assets	$122.2M	$124.1M	$128.7M
YoY Change	-2.01%	-3.56%	88.43%
TOTAL ASSETS
Total Short-Term Assets	$423.4M	$361.6M	$377.1M
Total Long-Term Assets	$122.2M	$124.1M	$128.7M
Total Assets	$545.7M	$485.7M	$505.8M
YoY Change	12.54%	-3.97%	-12.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.24M	$5.256M	$6.700M
YoY Change	23.36%	-21.55%	97.06%
Accrued Expenses	$15.40M	$11.90M	$20.30M
YoY Change	-17.44%	-41.38%	34.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.900M	$5.200M	$4.200M
YoY Change	44.12%	23.81%	-17.65%
Total Short-Term Liabilities	$74.32M	$51.60M	$83.50M
YoY Change	-2.35%	-38.2%	-17.24%
LONG-TERM LIABILITIES
Long-Term Debt	$221.9M	$221.3M	$212.9M
YoY Change	2.97%	3.95%	46.52%
Other Long-Term Liabilities	$66.70M	$42.50M	$22.60M
YoY Change	204.57%	88.05%	-70.22%
Total Long-Term Liabilities	$288.6M	$263.8M	$235.5M
YoY Change	21.57%	12.02%	6.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.32M	$51.60M	$83.50M
Total Long-Term Liabilities	$288.6M	$263.8M	$235.5M
Total Liabilities	$362.9M	$315.4M	$319.0M
YoY Change	15.78%	-1.13%	-0.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$907.0M	-$904.3M
YoY Change	7.78%
Common Stock	$1.077B	$1.074B
YoY Change	6.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$182.8M	$170.3M	$186.8M
YoY Change
Total Liabilities & Shareholders Equity	$545.7M	$485.7M	$505.8M
YoY Change	12.54%	-3.97%	-12.17%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	-$234.0M	-$37.60M	-$26.90M
YoY Change	1070.0%	39.78%	115.2%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$36.10M	-$24.90M	-$23.20M
YoY Change	-259.03%	7.33%	8.41%
INVESTING ACTIVITIES
Capital Expenditures	-$500.0K	-$100.0K	-$2.900M
YoY Change	-61.54%	-96.55%	262.5%
Acquisitions
YoY Change
Other Investing Activities	$5.500M	-$10.40M	-$2.700M
YoY Change	-83.63%	285.19%	-103.52%
Cash From Investing Activities	$5.000M	-$10.60M	-$5.700M
YoY Change	-84.52%	85.96%	-107.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.200M	34.40M	-900.0K
YoY Change	-300.0%	-3922.22%	125.0%
NET CHANGE
Cash From Operating Activities	36.10M	-24.90M	-23.20M
Cash From Investing Activities	5.000M	-10.60M	-5.700M
Cash From Financing Activities	-1.200M	34.40M	-900.0K
Net Change In Cash	39.90M	-1.100M	-29.80M
YoY Change	291.18%	-96.31%	-155.08%
FREE CASH FLOW
Cash From Operating Activities	$36.10M	-$24.90M	-$23.20M
Capital Expenditures	-$500.0K	-$100.0K	-$2.900M
Free Cash Flow	$36.60M	-$24.80M	-$20.30M
YoY Change	-271.03%	22.17%	-1.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	170277000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	315404000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	361586000	USD
CY2012Q3	us-gaap	Revenues Revenues	11601000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110178000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3105000	USD
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	43029000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22316000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	4773000	USD
CY2011Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	18000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26882000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26882000	USD
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99687000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99687000	shares
	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	64508000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	2175000	USD
	us-gaap	Revenues Revenues	66683000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8989000	USD
	us-gaap	Operating Expenses OperatingExpenses	119167000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52484000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	39647000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28046000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38345000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37639000	USD
	us-gaap	Revenues Revenues	82176000	USD
	us-gaap	Operating Expenses OperatingExpenses	124981000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42805000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63545000	USD
CY2011Q3	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	20189000	USD
CY2011Q3	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	524000	USD
CY2011Q3	us-gaap	Revenues Revenues	20713000	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39924000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2275000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1896000	USD
	us-gaap	Interest Expense InterestExpense	11624000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-267000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64754000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99620000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99620000	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2102000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62841000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12964000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40281000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19086000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89188000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	284379000	USD
	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	6	item
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	371872000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8934000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	2544000	USD
	isis	Purchases Of Strategic Investments PurchasesOfStrategicInvestments	359000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	75656000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1554000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	1625000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	4436000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1257000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14789000	USD
	us-gaap	Interest Paid InterestPaid	4647000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	1378000	USD
	isis	Capitalized Costs And Financing Liability CapitalizedCostsAndFinancingLiability	58748000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55263000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70052000	USD
	dei	Entity Registrant Name EntityRegistrantName	ISIS PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000874015
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101210828	shares
	isis	Number Of Categories Of Milestone Events NumberOfCategoriesOfMilestoneEvents	3	item
	isis	Number Of Stages Of Life Cycle Of Drugs NumberOfStagesOfLifeCycleOfDrugs	3	item
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4139000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6761000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2034000	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2364000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7596000	USD
CY2012Q3	isis	Available For Sale Securities Debt Maturities Within One Year Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage	0.63	pure
CY2012Q3	isis	Available For Sale Securities Debt Maturities After One Through Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage	0.24	pure
CY2012Q3	isis	Available For Sale Securities Debt Maturities After Two Through Three Years Percentage AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeYearsPercentage	0.13	pure
CY2012Q3	isis	Available For Sale Securities Debt Maturities Total Percentage AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage	1.00	pure
CY2012Q3	isis	Available For Sale Securities Debt Maturities Within Two Years Percentage AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage	0.87	pure
CY2012Q3	isis	Number Of Privately Held Companies In Which Entity Has Equity Investment NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment	3	company
CY2012Q3	isis	Number Of Publicly Held Companies In Which Entity Has Equity Investment NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment	3	company
CY2011Q4	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2012Q3	us-gaap	Cost Method Investments CostMethodInvestments	625000	USD
CY2011Q4	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2012Q3	us-gaap	Cost Method Investments Fair Value Disclosure CostMethodInvestmentsFairValueDisclosure	625000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	719000	USD
CY2012Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	2893000	USD
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	684000	USD
CY2012Q3	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	130000	USD
CY2012Q3	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	880000	USD
CY2011	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	880000	USD
CY2011Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	280094000	USD
CY2012Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	262825000	USD
CY2012Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	27	item
CY2012Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	49604000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7789000	USD
	isis	Proceeds From Equipment Financing Arrangement ProceedsFromEquipmentFinancingArrangement	9100000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table>
CY2011	isis	Variable Interest Entity Not Primary Beneficiary Number Of Entities VariableInterestEntityNotPrimaryBeneficiaryNumberOfEntities	6	item
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	846000	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-904329000	USD
CY2012Q3	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	11127000	USD
CY2012Q3	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	474000	USD
CY2012Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	259010000	USD
CY2012Q3	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	3476000	USD
	isis	Research And Development Revenue Under Collaborative Agreements ResearchAndDevelopmentRevenueUnderCollaborativeAgreements	80085000	USD
	isis	Licensing And Royalty Revenue LicensingAndRoyaltyRevenue	2091000	USD
CY2012Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6737000	USD
CY2012Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	23427000	USD
CY2012Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	36961000	USD
CY2012Q3	isis	Capital Lease And Other Long Term Borrowings Non Current CapitalLeaseAndOtherLongTermBorrowingsNonCurrent	8404000	USD
CY2012Q3	isis	Long Term Financing Obligation LongTermFinancingObligation	70375000	USD
CY2012Q3	us-gaap	Equity Method Investments EquityMethodInvestments	-5563000	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	102000	USD
CY2012Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1073658000	USD
CY2012Q3	us-gaap	Other Assets Current OtherAssetsCurrent	7800000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92598000	USD
CY2012Q3	isis	Securities Amortized Cost Basis SecuritiesAmortizedCostBasis	260942000	USD
CY2011Q4	isis	Securities Amortized Cost Basis SecuritiesAmortizedCostBasis	280939000	USD
CY2012Q3	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	-130000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2012Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4770000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84563000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37761000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28434000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66867000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61225000	USD
CY2012Q3	isis	Licenses Net LicensesNet	7191000	USD
CY2012Q3	isis	Patents Net PatentsNet	18180000	USD
CY2012Q3	isis	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	6126000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5256000	USD
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5836000	USD
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11900000	USD
CY2012Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5182000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36551000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3096000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115700000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9281000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1139000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	408000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1485000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	5937000	USD
	us-gaap	Interest Expense InterestExpense	16335000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	19000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4770000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-706000	USD
CY2012Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	142500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-704000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100680000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100351000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100680000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100351000	shares
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-122000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1616000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34159000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	172581000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	189397000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1033000	USD
	isis	Payments To Acquire Licenses And Other Assets PaymentsToAcquireLicensesAndOtherAssets	2779000	USD
	isis	Purchases Of Strategic Investments PurchasesOfStrategicInvestments	40000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	7579000	USD
	us-gaap	Interest Paid InterestPaid	5584000	USD
	isis	Noncash Capital And Patent Expenditures NoncashCapitalAndPatentExpenditures	839000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	194689000	USD
	us-gaap	Repayments Of Subordinated Debt RepaymentsOfSubordinatedDebt	163718000	USD

Files In Submission

Name	View Source	Status
0001104659-12-074712-index-headers.html	Edgar Link	pending
0001104659-12-074712-index.html	Edgar Link	pending
0001104659-12-074712.txt	Edgar Link	pending
0001104659-12-074712-xbrl.zip	Edgar Link	pending
a12-19742_110q.htm	Edgar Link	pending
a12-19742_1ex10d1.htm	Edgar Link	pending
a12-19742_1ex31d1.htm	Edgar Link	pending
a12-19742_1ex31d2.htm	Edgar Link	pending
a12-19742_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g197421kei001.gif	Edgar Link	pending
isis-20120930.xml	Edgar Link	completed
isis-20120930.xsd	Edgar Link	pending
isis-20120930_cal.xml	Edgar Link	unprocessable
isis-20120930_def.xml	Edgar Link	unprocessable
isis-20120930_lab.xml	Edgar Link	unprocessable
isis-20120930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IONS
IONIS PHARMACEUTICALS INC Stock $ions

2012 Q4 Form 10-Q Financial Statement

#000110465912074712 Filed on November 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS IONIS PHARMACEUTICALS INC Stock $ions

2012 Q4 Form 10-Q Financial Statement

#000110465912074712 Filed on November 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IONS
IONIS PHARMACEUTICALS INC Stock $ions